CA Patent

CA2852995C — Ocular composition containing bromfenac with increased bioavailability

Assigned to Bausch and Lomb Inc · Expires 2016-03-29 · 10y expired

What this patent protects

Formulations and methods that provided enhanced bromfenac penetration into ocular tissue when topically administered, compared to the currently available BROMDAY formulation and method when topically administered. The formulations and methods did so while retaining the patient co…

USPTO Abstract

Formulations and methods that provided enhanced bromfenac penetration into ocular tissue when topically administered, compared to the currently available BROMDAY formulation and method when topically administered. The formulations and methods did so while retaining the patient convenience of a once-daily administration and advantageously lowered the bromfenac concentration dosed to the patient.

Drugs covered by this patent

Patent Metadata

Patent number
CA2852995C
Jurisdiction
CA
Classification
—
Expires
2016-03-29
Drug substance claim
No
Drug product claim
No
Assignee
Bausch and Lomb Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.